Apollon Wealth Management LLC Has $15.26 Million Stake in Johnson & Johnson (NYSE:JNJ)

Apollon Wealth Management LLC lifted its position in Johnson & Johnson (NYSE:JNJ) by 20.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 105,500 shares of the company’s stock after purchasing an additional 18,082 shares during the quarter. Apollon Wealth Management LLC’s holdings in Johnson & Johnson were worth $15,257,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of JNJ. IFS Advisors LLC raised its stake in Johnson & Johnson by 138.9% during the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after acquiring an additional 100 shares in the last quarter. Highline Wealth Partners LLC acquired a new position in Johnson & Johnson during the third quarter worth $31,000. Bay Harbor Wealth Management LLC acquired a new position in Johnson & Johnson during the fourth quarter worth $32,000. RPg Family Wealth Advisory LLC acquired a new position in Johnson & Johnson during the third quarter worth $35,000. Finally, Mowery & Schoenfeld Wealth Management LLC raised its stake in Johnson & Johnson by 58.7% during the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock worth $40,000 after acquiring an additional 91 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on JNJ shares. Bank of America decreased their target price on Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating on the stock in a report on Thursday, January 23rd. Raymond James decreased their target price on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a report on Thursday, January 23rd. Wolfe Research started coverage on Johnson & Johnson in a report on Friday, November 15th. They set an “outperform” rating and a $190.00 target price on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a report on Wednesday, October 16th. Finally, StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 25th. Nine equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $170.67.

Johnson & Johnson Price Performance

Shares of JNJ opened at $156.18 on Wednesday. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $168.85. The stock has a market cap of $376.02 billion, a P/E ratio of 23.49, a price-to-earnings-growth ratio of 2.46 and a beta of 0.52. The stock’s 50-day moving average price is $147.40 and its two-hundred day moving average price is $156.04.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The firm had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22.44 billion. During the same quarter last year, the business earned $2.29 earnings per share. The company’s revenue was up 5.3% compared to the same quarter last year. On average, equities analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.18%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger purchased 1,000 shares of the company’s stock in a transaction dated Thursday, December 12th. The shares were bought at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the transaction, the director now directly owns 1,000 shares in the company, valued at $147,220. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.